guidance raise

Kinikska Pharmaceuticals surged 24% after Q1 earnings beat. Arcalyst revenue jumped to $214M; net income more than doubled. Company raised full-year Arcalyst guidance to $930-945M.

Solaris Energy stock surges 5% after Q1 earnings crush expectations, with revenue at $196M vs. $183M forecast and EPS nearly tripling. AI data center demand drives outlook.

Celestica stock plunged 15.7% despite beating earnings and raising full-year revenue guidance to $19B and EPS to $10.15, signaling market valuation concerns.

Celestica beat Q1 earnings estimates with $2.16 EPS and $4.05B revenue, raising full-year guidance, yet shares fell 7.11% in after-hours trading.

$APOG surges 10.65% after beating Q4 earnings and providing upbeat fiscal 2027 guidance, driven by pricing gains and operational improvements.

Edwards Lifesciences beats Q1 earnings expectations, reporting 78-cent EPS and $1.65B revenue while raising 2026 guidance on strong heart valve device growth.

Intel surges 27.6% on Q1 earnings beat, with AI revenue reaching 60% of sales and growing 40% yearly, while Q2 guidance more than doubles analyst estimates.

Thermo Fisher beats Q1 earnings, raises FY26 guidance on strong bioproduction demand, but warns of modest inflation risks from Middle East tensions.

West Pharmaceutical beats Q1 earnings with 21% sales growth driven by GLP-1 demand, raises full-year guidance, and launches $1B share repurchase program.

Finnish pharma $ORION reported 17.8% Q1 revenue growth to €417.7M, raised full-year guidance citing Nubeqa royalties and pipeline progress.

Elevance Health beat Q1 earnings estimates and raised 2026 guidance, but elevated Medicaid costs and a $935M CMS accrual signal underlying margin pressures.

UnitedHealth raises 2026 earnings guidance above $18.25 per share after Q1 beat. Stock rises 3.2% despite overbought signals and Medicare drug coverage challenges.

Vertiv reported 30% YoY revenue growth to $2.65B, beating EPS estimates, but shares fell 4.94% after results announcement.

$GEV surges 7.74% after crushing Q1 earnings and raising 2026 guidance, driven by $13B backlog growth amid strong power demand.

UnitedHealth stock surged 8.51% after Q1 earnings beat. Company raised 2026 EPS guidance to $18.25+, citing improved medical trends and operational gains.

UnitedHealth beat Q1 earnings estimates and raised 2026 guidance, citing improved medical cost ratios and operational efficiency gains.

ASML raises 2026 revenue guidance to €36-40 billion on 13% Q1 growth, signaling sustained AI chip manufacturing demand and supporting broader Nasdaq upside.

Prologis raises 2026 guidance after Q1 beat, reporting $1.50 core FFO and raising full-year outlook on strong leasing and data center expansion.

ESCO Technologies to acquire Megger Group for $2.35B, expanding utility capabilities with $60M cost synergies and raising 2026 guidance.

J&J reported 9.9% Q1 revenue growth with raised guidance, though EPS fell 2.5% due to patent losses. Technical setup suggests 20% upside potential supported by strong pipeline expectations.